UriAryehLopatinMD

Physician

Are you Dr. Lopatin?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. Uri Lopatin, MD is an infectious disease specialist in San Francisco, California. He is currently licensed to practice medicine in New York.

National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2003 - 2005
NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2003
University of WashingtonInternship, Internal Medicine, 2000 - 2001
Rutgers New Jersey Medical SchoolClass of 2000

PubMed

6 citations
Evaluation ofantiviral activity of SARS-CoV-2 Minhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
Xiao Tong, Walter Keung, Lee D Arnold, Laura J Stevens, Andrea J Pruijssers
Antimicrobial Agents and Chemotherapy. 2023-11-15
21 citations
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff
Journal of Hepatology. 2022-11-01
12 citations
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff
Journal of Hepatology. 2022-09-01

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsAugust 26th, 2021
Pardes Biosciences Appoints Deborah M. Autor, J.D. (’92) and Laura J. Hamill to Board of DirectorsAugust 5th, 2021
Shasqi Completes $10 Million Series A FinancingOctober 31st, 2019
Join now to see all